radiopharmaceuticals
Telix Pharmaceuticals, Cardinal Health Partner to Distribute Prostate Cancer Imaging Agent in US
Cardinal is using its own cyclotron installations to produce Gozellix for distribution across a range of US locations.
Telix Pharmaceuticals Begins Phase I Trial of Radiopharmaceutical Agent in Sarcoma
The firm is evaluating its radiopharmaceutical imaging agent targeting PDGFRα, TLX300-CDx, in advanced or metastatic soft tissue sarcoma.
FDA Expands Pluvicto Indication to Earlier Line of Treatment for PSMA-Positive Prostate Cancer
Prostate cancer patients who have not yet received chemotherapy are now eligible for treatment with Pluvicto.
FDA Approves Telix Radiopharmaceutical Imaging Agent Gozellix to ID PSMA-Positive Prostate Cancer
The PSMA-PET imaging agent will be used for patients who have suspected metastasis and those with suspected cancer recurrence.
Precision Oncology Investments Continue Amid Stubborn Operational Difficulties, Survey Shows
Premium
Precision Medicine Online's 2024 survey shows biomarker test expansion but low clinical trial enrollment and long wait times for advanced therapies.